Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(ARTC, STEM) - Watch List for Wednesday Nov. 3, 2010

|Includes: ArthroCare Corporation (ARTC), MBOT




artc ARTC, ArthroCare Corporation

ARTC is a highly innovative, multi-business medical device company that develops, manufactures, and markets minimally invasive surgical products.

With these products, ARTC targets a multi-billion dollar market across several medical specialties, significantly improving existing surgical procedures and enabling new, minimally invasive procedures.

** ARTC reported that it has received clearance from the U.S. Food and Drug Administration (FDA) for its SpeedFix Suture Anchor system (SpeedFix™). SpeedFix, a push-in anchor made of PEEK (polyether-etherketone) polymer, is designed for the repair of certain tears of the labrum in a shoulder.

SpeedFix anchors, which are double-loaded with ARTC’s high-strength MagnumWire® suture, provide surgeons with independent bone locking, suture tensioning and suture locking to ensure tissues are securely attached to the glenoid.

SpeedFix is expected to complement ARTC’s broad line of suture anchors and ARTC’s suture passing technology, including FirstPass™.

More about ARTC at


stemcellslogo  STEM, StemCells, Inc.

STEM is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery.

In its therapeutic product development programs, STEM is targeting diseases of the central nervous system and liver.

** STEM has been awarded cash grants by the U.S. government totaling $977,917 for projects related to the Company's development of cell-based therapeutics targeting the central nervous system (NYSE:CNS) and the liver.

The funds will be used to advance the preclinical and clinical development of STEM's HuCNS-SC(NYSE:R) product candidate (purified human neural stem cells) for diseases and disorders affecting the brain, the spinal cord and the eye, as well as the further development of STEM's hLEC(NYSE:TM) human liver engrafting cells.

All four project applications submitted by STEM were approved, and STEM expects to receive payment for the entire grant amounts during the fourth quarter of 2010.

More about STEM at


Signup for FREE Daily Stock Alerts From


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.